Head-to-head evidence
SH-1028 vs TY-9591
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
SH-1028
Developed by Nanjing Sanhome Pharmaceutical
NCT04239833 · Phase 3 · status unknown
In this randomized, double-blind, active-controlled Phase 3 trial in patients with EGFR-mutated non-small-cell lung cancer, SH-1028 significantly extended progression-free survival compared with gefitinib, the standard EGFR-targeted therapy (median 19.3 months vs 9.8 months).
Next expected readout: February 2028 · NCT06080776 (registry estimate)
TY-9591
Developed by TYK Medicines, Inc.
NCT05146219 · Phase 2 · completed
The study treated 29 participants in a single arm without randomization, blinding, or a control group. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2027 · NCT06672068 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SH-1028's landscape · TY-9591's landscape